|
G |
Avp |
arginine vasopressin |
multiple interactions |
EXP |
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of AVP protein] |
CTD |
PMID:11102496 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO |
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid results in decreased expression of FN1 mRNA |
CTD |
PMID:18210741 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]] |
CTD |
PMID:32941855 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Silicon Dioxide analog results in increased expression of IL6 protein] |
CTD |
PMID:24793913 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
ISO |
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]] |
CTD |
PMID:24912985 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Oxt |
oxytocin/neurophysin I prepropeptide |
multiple interactions |
EXP |
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of OXT protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of OXT protein] |
CTD |
PMID:11102496 |
|
NCBI chr 3:117,782,650...117,783,490
Ensembl chr 3:117,782,650...117,783,490
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
multiple interactions |
ISO |
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein] pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein] |
CTD |
PMID:21638035 PMID:31263019 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [zinc chloride results in increased expression of PARP1 protein] |
CTD |
PMID:22253048 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]] |
CTD |
PMID:32941855 |
|
NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822
|
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
cangrelor results in decreased expression of and results in decreased activity of F3 protein; Indomethacin promotes the reaction [cangrelor results in decreased expression of and results in decreased activity of F3 protein] |
CTD |
PMID:20200314 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Uridine Diphosphate results in increased activity of GPR17 protein] |
CTD |
PMID:18974869 |
|
NCBI chr18:23,576,212...23,583,177
Ensembl chr18:23,577,242...23,582,966
|
|
G |
Itga2b |
integrin subunit alpha 2b |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] |
CTD |
PMID:18404433 |
|
NCBI chr10:87,408,532...87,426,055
Ensembl chr10:87,408,536...87,426,168
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] |
CTD |
PMID:18404433 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
P2ry12 |
purinergic receptor P2Y12 |
multiple interactions affects response to substance decreases activity |
ISO |
[cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased abundance of phosphatidylinositol 3,4,5-triphosphate; [cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased phosphorylation of SYK protein P2RY12 gene polymorphism affects the susceptibility to cangrelor cangrelor results in decreased activity of P2RY12 protein |
CTD |
PMID:12606772 PMID:20126830 PMID:22273509 |
|
NCBI chr 2:143,481,468...143,523,340
Ensembl chr 2:143,481,430...143,523,361
|
|
G |
Pf4 |
platelet factor 4 |
multiple interactions |
ISO |
cangrelor inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased secretion of PF4 protein] |
CTD |
PMID:22273509 |
|
NCBI chr14:17,298,438...17,299,148
Ensembl chr14:17,298,308...17,299,365
|
|
G |
Selp |
selectin P |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]] |
CTD |
PMID:18404433 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Syk |
spleen associated tyrosine kinase |
multiple interactions |
ISO |
[cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased phosphorylation of SYK protein |
CTD |
PMID:12606772 |
|
NCBI chr17:12,604,615...12,678,437
Ensembl chr17:12,604,619...12,661,410
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases uptake decreases expression increases secretion decreases activity affects response to substance |
ISO EXP |
ABCB1 gene affects the reaction [CYP2C19 gene affects the susceptibility to clopidogrel] [Aspirin results in increased expression of ABCB1 protein] which results in decreased uptake of clopidogrel ABCB1 protein results in decreased uptake of clopidogrel clopidogrel results in decreased expression of ABCB1 mRNA; clopidogrel results in decreased expression of ABCB1 protein ABCB1 protein results in increased secretion of clopidogrel clopidogrel results in decreased activity of ABCB1 protein ABCB1 gene affects the susceptibility to clopidogrel; ABCB1 gene polymorphism affects the susceptibility to clopidogrel; ABCB1 gene SNP affects the susceptibility to clopidogrel |
CTD |
PMID:17112805 PMID:19106083 PMID:19934793 PMID:20180610 PMID:21900887 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of ALOX5AP mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
|
|
G |
Arhgap31 |
Rho GTPase activating protein 31 |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of ARHGAP31 mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr11:62,038,635...62,151,564
Ensembl chr11:62,038,635...62,151,564
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases secretion |
ISO |
clopidogrel results in decreased secretion of BDNF protein |
CTD |
PMID:21803431 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
C4b |
complement C4B (Chido blood group) |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of C4B mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681
|
|
G |
Cabin1 |
calcineurin binding protein 1 |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CABIN1 mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr20:12,893,314...13,015,357
Ensembl chr20:12,893,358...13,015,357
|
|
G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2 |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CAMKK2 mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr12:33,791,023...33,845,000
Ensembl chr12:33,791,052...33,843,279
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
increases expression |
ISO |
clopidogrel results in increased expression of CCL11 mRNA |
CTD |
PMID:19155974 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases expression |
ISO |
clopidogrel results in increased expression of CCL4 mRNA |
CTD |
PMID:16856976 |
|
NCBI chr10:68,466,469...68,467,941
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
clopidogrel results in increased expression of CCL5 mRNA |
CTD |
PMID:16856976 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Cd40lg |
CD40 ligand |
multiple interactions decreases expression |
ISO |
clopidogrel inhibits the reaction [Adenosine Diphosphate results in increased expression of CD40LG protein] clopidogrel results in decreased expression of CD40LG protein Clopidogrel inhibits the reaction [Adenosine Diphosphate results in increased expression of CD40LG protein]; Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CD40LG protein] |
CTD |
PMID:11297035 PMID:17043144 PMID:19155974 PMID:30537341 |
|
NCBI chr X:135,127,119...135,138,302
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Clcn7 |
chloride voltage-gated channel 7 |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CLCN7 mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr10:14,151,758...14,177,130
Ensembl chr10:14,151,758...14,177,130
|
|
G |
Csf2rb |
colony stimulating factor 2 receptor subunit beta |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2RB mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr 7:109,876,919...109,901,589
Ensembl chr 7:109,886,425...109,904,157
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Clopidogrel results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions increases oxidation |
ISO |
CYP1A2 protein results in increased oxidation of and results in increased cleavage of Clopidogrel metabolite; furafylline inhibits the reaction [CYP1A2 protein results in increased oxidation of Clopidogrel] CYP1A2 protein results in increased oxidation of clopidogrel |
CTD |
PMID:19170597 PMID:19812348 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Clopidogrel results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases oxidation increases expression multiple interactions |
ISO |
CYP2B6 protein results in increased oxidation of clopidogrel Clopidogrel results in increased expression of CYP2B6 mRNA [Clopidogrel co-treated with NR1I3 protein mutant form] results in increased expression of CYP2B6 mRNA |
CTD |
PMID:19812348 PMID:31312845 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
multiple interactions increases oxidation increases metabolic processing decreases response to substance increases response to substance decreases metabolic processing affects abundance affects response to substance |
ISO |
ABCB1 gene affects the reaction [CYP2C19 gene affects the susceptibility to clopidogrel]; CYP2C19 gene affects the reaction [clopidogrel affects the phosphorylation of VASP protein]; CYP2C19 gene affects the susceptibility to [Adenosine Diphosphate co-treated with clopidogrel]; CYP2C19 gene polymorphism results in decreased metabolism of and results in decreased activity of clopidogrel; CYP2C19 gene SNP promotes the reaction [CYP2C19 gene SNP affects the susceptibility to clopidogrel]; CYP2C19 protein results in increased metabolism of and results in increased activity of clopidogrel; CYP2C19 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite; CYP2C9 gene affects the reaction [CYP2C19 gene affects the susceptibility to clopidogrel]; N-3-benzylnirvanol inhibits the reaction [CYP2C19 protein results in increased oxidation of clopidogrel]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of clopidogrel]; P2RY12 gene SNP affects the reaction [CYP2C19 gene SNP affects the susceptibility to clopidogrel] CYP2C19 protein results in increased metabolism of clopidogrel CYP2C19 gene polymorphism results in decreased susceptibility to clopidogrel; CYP2C19 gene SNP results in decreased susceptibility to clopidogrel CYP2C19 gene polymorphism results in increased susceptibility to clopidogrel; CYP2C19 gene SNP results in increased susceptibility to clopidogrel CYP2C19 gene polymorphism results in decreased metabolism of clopidogrel; CYP2C19 gene SNP results in decreased metabolism of clopidogrel CYP2C19 gene polymorphism affects the abundance of clopidogrel metabolite CYP2C19 gene affects the susceptibility to clopidogrel; CYP2C19 gene polymorphism affects the susceptibility to clopidogrel; CYP2C19 gene SNP affects the susceptibility to clopidogrel |
CTD |
PMID:16772608 PMID:17697139 PMID:17900275 PMID:18532997 PMID:18577829 PMID:19106083 PMID:19106084 PMID:19170597 PMID:19429918 PMID:19463375 PMID:19496924 PMID:19576320 PMID:19706858 PMID:19812348 PMID:19926050 PMID:19934793 PMID:20083681 PMID:20166430 PMID:20180610 PMID:20217574 PMID:20620727 PMID:20978260 More...
|
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
multiple interactions |
ISO |
CYP2C8 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite |
CTD |
PMID:19170597 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions |
ISO |
CYP2D6 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite |
CTD |
PMID:19170597 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression increases response to substance increases degradation affects response to substance multiple interactions |
ISO |
Clopidogrel results in increased expression of CYP3A4 mRNA CYP3A4 protein results in increased susceptibility to Clopidogrel CYP3A4 protein results in increased degradation of Clopidogrel CYP3A4 gene polymorphism affects the susceptibility to Clopidogrel CYP3A4 protein results in increased oxidation of and results in increased cleavage of Clopidogrel metabolite; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased degradation of Clopidogrel]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Clopidogrel] |
CTD |
PMID:16645157 PMID:19170597 PMID:22651985 PMID:31312845 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
affects response to substance multiple interactions |
ISO |
CYP3A5 gene polymorphism affects the susceptibility to clopidogrel CYP3A5 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite |
CTD |
PMID:16754899 PMID:19170597 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of DUSP1 mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr10:16,680,489...16,683,276
|
|
G |
Eif1a |
eukaryotic translation initiation factor 1A |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of EIF1A mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr18:39,325,695...39,338,043
Ensembl chr18:39,325,202...39,338,696
|
|
G |
F2 |
coagulation factor II |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [F2 protein results in increased expression of SELP protein] |
CTD |
PMID:17043144 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
affects response to substance |
ISO |
F2R gene SNP affects the susceptibility to clopidogrel |
CTD |
PMID:16194864 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of F3 protein] |
CTD |
PMID:30537341 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
ISO |
Clopidogrel results in decreased expression of G6PC1 mRNA |
CTD |
PMID:31312845 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
clopidogrel results in decreased expression of ICAM1 mRNA; clopidogrel results in decreased expression of ICAM1 protein |
CTD |
PMID:19155974 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il10ra |
interleukin 10 receptor subunit alpha |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of IL10RA mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr 8:45,563,009...45,578,041
Ensembl chr 8:45,563,137...45,578,061
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of IL13 mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:30537341 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
increases expression |
ISO |
clopidogrel results in increased expression of IL4 mRNA |
CTD |
PMID:19155974 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression increases response to substance |
ISO |
clopidogrel promotes the reaction [Silicon Dioxide analog results in increased expression of IL6 protein] clopidogrel results in decreased expression of IL6 mRNA IL6 protein results in increased susceptibility to clopidogrel clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] |
CTD |
PMID:17537833 PMID:19155974 PMID:24793913 PMID:24849676 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itga2 |
integrin subunit alpha 2 |
multiple interactions |
ISO |
ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Adenosine Diphosphate]; ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Epinephrine]; ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel] |
CTD |
PMID:15205592 PMID:16214444 |
|
NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Itgb3 |
integrin subunit beta 3 |
decreases response to substance affects response to substance |
ISO |
ITGB3 gene SNP results in decreased susceptibility to clopidogrel ITGB3 gene SNP affects the susceptibility to clopidogrel |
CTD |
PMID:15166949 PMID:19530321 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Ltb4r |
leukotriene B4 receptor |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of LTB4R1 mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr15:29,263,126...29,265,716
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK3 mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mccc2 |
methylcrotonyl-CoA carboxylase subunit 2 |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of MCCC2 mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr 2:31,304,927...31,375,978
Ensembl chr 2:31,304,932...31,375,972
|
|
G |
Med1 |
mediator complex subunit 1 |
multiple interactions |
ISO |
Clopidogrel promotes the reaction [MED1 protein binds to NR1I3 protein alternative form] |
CTD |
PMID:31312845 |
|
NCBI chr10:83,145,538...83,189,260
Ensembl chr10:83,145,568...83,189,299
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity |
EXP |
clopidogrel results in decreased activity of MMP9 protein |
CTD |
PMID:20195827 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Clopidogrel inhibits the reaction [1-Naphthylisothiocyanate results in increased activity of MPO protein]; Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased activity of MPO protein] |
CTD |
PMID:20133375 PMID:30537341 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
affects localization multiple interactions |
ISO |
Clopidogrel affects the localization of NR1I3 protein mutant form [Clopidogrel co-treated with NR1I3 protein mutant form] results in increased expression of CYP2B6 mRNA; Clopidogrel binds to and results in increased activity of NR1I3 protein alternative form; Clopidogrel inhibits the reaction [ethyl (5-(diethylglycyl)-10,11-dihydro-5H-dibenzo(b,f)azepin-3-yl)carbamate results in decreased activity of NR1I3 protein]; Clopidogrel promotes the reaction [MED1 protein binds to NR1I3 protein alternative form] |
CTD |
PMID:31312845 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Ocln |
occludin |
decreases expression multiple interactions |
ISO |
clopidogrel results in decreased expression of OCLN protein SB 203580 inhibits the reaction [clopidogrel results in decreased expression of OCLN protein] |
CTD |
PMID:23220562 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
P2ry12 |
purinergic receptor P2Y12 |
multiple interactions increases response to substance affects response to substance |
ISO |
clopidogrel binds to and results in decreased activity of P2RY12 protein; P2RY12 gene SNP affects the reaction [CYP2C19 gene SNP affects the susceptibility to clopidogrel] P2RY12 protein results in increased susceptibility to clopidogrel P2RY12 gene affects the susceptibility to clopidogrel; P2RY12 gene SNP affects the susceptibility to clopidogrel; P2RY12 protein affects the susceptibility to clopidogrel |
CTD |
PMID:11413167 PMID:15933261 PMID:18404433 PMID:18485500 PMID:18577829 PMID:20031628 PMID:22129738 More...
|
|
NCBI chr 2:143,481,468...143,523,340
Ensembl chr 2:143,481,430...143,523,361
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression |
ISO |
Clopidogrel results in increased expression of PCK1 mRNA |
CTD |
PMID:31312845 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
decreases expression |
ISO |
clopidogrel results in decreased expression of PDGFB mRNA; clopidogrel results in decreased expression of PDGFB protein |
CTD |
PMID:19155974 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pon1 |
paraoxonase 1 |
affects response to substance multiple interactions |
ISO |
PON1 gene polymorphism affects the susceptibility to clopidogrel PON1 protein results in increased metabolism of and results in increased activity of clopidogrel |
CTD |
PMID:21170047 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of PRKCB mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Ran |
RAN, member RAS oncogene family |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of RAN mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276
|
|
G |
S100a11 |
S100 calcium binding protein A11 |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of S100A11 mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr 2:179,191,504...179,197,098
Ensembl chr 2:179,191,715...179,197,044
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
ISO |
Clopidogrel results in decreased expression of SCD mRNA |
CTD |
PMID:31312845 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Sele |
selectin E |
decreases expression |
ISO |
clopidogrel results in decreased expression of SELE mRNA; clopidogrel results in decreased expression of SELE protein |
CTD |
PMID:19155974 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Selp |
selectin P |
multiple interactions decreases expression |
ISO |
Clopidogrel inhibits the reaction [F2 protein results in increased expression of SELP protein]; Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of SELP protein] clopidogrel results in decreased expression of SELP mRNA; clopidogrel results in decreased expression of SELP protein |
CTD |
PMID:17043144 PMID:19155974 PMID:30537341 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Slc3a1 |
solute carrier family 3 member 1 |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of SLC3A1 mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr 6:9,608,169...9,641,881
Ensembl chr 6:9,608,178...9,641,907
|
|
G |
Stat2 |
signal transducer and activator of transcription 2 |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of STAT2 mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr 7:702,565...718,349
Ensembl chr 7:702,495...718,967
|
|
G |
Sucla2 |
succinate-CoA ligase ADP-forming subunit beta |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of SUCLA2 mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr15:48,752,356...48,805,495
Ensembl chr15:48,752,312...48,805,138
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of TGFB1 mRNA] clopidogrel results in increased expression of TGFB1 mRNA |
CTD |
PMID:19155974 PMID:19172522 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Thbs1 |
thrombospondin 1 |
increases expression |
ISO |
clopidogrel results in increased expression of THBS1; clopidogrel results in increased expression of THBS1 mRNA; clopidogrel results in increased expression of THBS1 protein |
CTD |
PMID:9447704 PMID:11875746 |
|
NCBI chr 3:105,056,286...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Thrsp |
thyroid hormone responsive |
increases expression |
ISO |
Clopidogrel results in increased expression of THRSP mRNA |
CTD |
PMID:31312845 |
|
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
|
|
G |
Tjp1 |
tight junction protein 1 |
decreases expression multiple interactions |
ISO |
clopidogrel results in decreased expression of TJP1 protein SB 203580 inhibits the reaction [clopidogrel results in decreased expression of TJP1 protein] |
CTD |
PMID:23220562 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tmem69 |
transmembrane protein 69 |
multiple interactions |
ISO |
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of TMEM69 mRNA] |
CTD |
PMID:19172522 |
|
NCBI chr 5:130,004,888...130,008,466
Ensembl chr 5:130,004,901...130,010,655
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
clopidogrel results in increased expression of TNF mRNA Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:19155974 PMID:30537341 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
clopidogrel results in increased expression of TP53 mRNA; clopidogrel results in increased expression of TP53 protein |
CTD |
PMID:9447704 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
multiple interactions |
ISO |
CYP2C19 gene affects the reaction [clopidogrel affects the phosphorylation of VASP protein] |
CTD |
PMID:16772608 |
|
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
|
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
Prasugrel Hydrochloride inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of BDNF protein] |
CTD |
PMID:34174262 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Prasugrel Hydrochloride inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:34174262 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Mir22 |
microRNA 22 |
multiple interactions |
EXP |
Prasugrel Hydrochloride inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of MIR22 mRNA] |
CTD |
PMID:34174262 |
|
NCBI chr10:60,307,039...60,307,133
Ensembl chr10:60,307,039...60,307,133
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP |
Prasugrel Hydrochloride inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased sumoylation of NFKBIA protein] |
CTD |
PMID:34174262 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
P2ry12 |
purinergic receptor P2Y12 |
multiple interactions |
ISO |
Prasugrel Hydrochloride binds to and results in decreased activity of P2RY12 protein |
CTD |
PMID:17681285 |
|
NCBI chr 2:143,481,468...143,523,340
Ensembl chr 2:143,481,430...143,523,361
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP |
Prasugrel Hydrochloride inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of SIRT1 protein] |
CTD |
PMID:34174262 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Ube2i |
ubiquitin-conjugating enzyme E2I |
multiple interactions |
EXP |
Prasugrel Hydrochloride inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of UBE2I protein] |
CTD |
PMID:34174262 |
|
NCBI chr10:14,277,749...14,294,681
Ensembl chr10:69,701,618...69,702,443 Ensembl chr10:69,701,618...69,702,443
|
|
|
G |
P2rx5 |
purinergic receptor P2X 5 |
affects transport |
EXP |
PPADS CHEBI:34941 affects transport ion flux of P2rx5 receptor |
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:57,777,737...57,789,426
Ensembl chr10:57,777,819...57,789,423
|
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions |
EXP |
Suramin inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]] |
CTD |
PMID:12044622 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP |
Suramin inhibits the reaction [Glucose results in increased activity of CASP1 protein] |
CTD |
PMID:21832250 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of CASP3]; Suramin inhibits the reaction [Clodronic Acid results in increased expression of CASP3] |
CTD |
PMID:19448140 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
increases expression |
ISO |
Suramin results in increased expression of CHRNA7 protein |
CTD |
PMID:23516405 |
|
NCBI chr 1:116,715,286...116,837,223
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Suramin inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:18612546 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Suramin results in decreased activity of CYP1A2 protein |
CTD |
PMID:11124226 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
Suramin inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:22167199 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases activity |
ISO |
Suramin results in decreased activity of CYP2C19 protein |
CTD |
PMID:11124226 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein] |
CTD |
PMID:9710602 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
Suramin results in increased expression of FGF2 |
CTD |
PMID:8394679 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
increases expression |
ISO |
Suramin results in increased expression of FGF5 |
CTD |
PMID:8394679 |
|
NCBI chr14:11,325,334...11,346,570
Ensembl chr14:11,325,334...11,345,997
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
affects localization multiple interactions |
ISO |
Suramin affects the localization of FGF7 protein Suramin inhibits the reaction [FGF7 protein binds to FGFR2 protein] |
CTD |
PMID:15733146 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
multiple interactions |
ISO |
Suramin inhibits the reaction [FGF7 protein binds to FGFR2 protein] |
CTD |
PMID:15733146 |
|
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
multiple interactions |
ISO |
Suramin inhibits the reaction [Poly I-C results in decreased expression of FMR1 protein] |
CTD |
PMID:23516405 |
|
NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050
|
|
G |
Gusb |
glucuronidase, beta |
decreases activity |
EXP |
suramin decreases activity of beta-glucuronidase in rat spleen, kidney, and lung |
RGD |
PMID:2879381 |
RGD:42724461 |
NCBI chr12:26,701,191...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Hpgds |
hematopoietic prostaglandin D synthase |
decreases activity |
ISO |
Suramin results in decreased activity of HPGDS protein |
CTD |
PMID:25603235 |
|
NCBI chr 4:94,368,426...94,397,931
Ensembl chr 4:94,373,342...94,397,883
|
|
G |
Il10 |
interleukin 10 |
multiple interactions decreases activity |
ISO |
Suramin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of IL10 protein] Suramin results in decreased activity of IL10 protein |
CTD |
PMID:15914193 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
increases expression |
ISO |
Suramin results in increased expression of IL12B protein |
CTD |
PMID:15914193 |
|
NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; Suramin inhibits the reaction [Silicon Dioxide analog results in increased expression of IL6 protein]; Suramin inhibits the reaction [Uridine Triphosphate results in increased expression of IL6 protein] Suramin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] |
CTD |
PMID:24793913 PMID:24849676 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lmna |
lamin A/C |
multiple interactions |
ISO |
Suramin inhibits the reaction [LMNA protein binds to and results in increased activity of SIRT1 protein] |
CTD |
PMID:23217256 |
|
NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
Suramin inhibits the reaction [arsenic acid results in increased activity of MAPK1 protein]; Suramin inhibits the reaction [arsenite results in increased activity of MAPK1 protein]; Suramin inhibits the reaction [Estradiol results in increased phosphorylation of MAPK1 protein]; Suramin inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of MAPK1 protein] Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK1 protein] Suramin inhibits the reaction [2,6-di-tert-butyl-4-hydroperoxy-4-methyl-2,5-cyclohexadienone results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:8758915 PMID:9710602 PMID:14674888 PMID:15930183 PMID:18612546 PMID:23516405 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
Suramin inhibits the reaction [arsenic acid results in increased activity of MAPK3 protein]; Suramin inhibits the reaction [arsenite results in increased activity of MAPK3 protein]; Suramin inhibits the reaction [Estradiol results in increased phosphorylation of MAPK3 protein]; Suramin inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of MAPK3 protein] Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK3 protein] Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:9710602 PMID:14674888 PMID:15930183 PMID:18612546 PMID:23516405 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
P2rx1 |
purinergic receptor P2X 1 |
affects binding |
EXP |
Suramin binds to P2rx1 protein |
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:57,618,586...57,633,648
Ensembl chr10:57,618,586...57,633,623
|
|
G |
P2rx2 |
purinergic receptor P2X 2 |
affects activity |
EXP |
suramin affects activity of rat P2x2 receptor in transfected glial cells |
RGD |
PMID:16388598 |
RGD:1642662 |
NCBI chr12:46,338,979...46,342,891
Ensembl chr12:46,339,549...46,342,891
|
|
G |
P2rx3 |
purinergic receptor P2X 3 |
multiple interactions |
EXP |
Suramin inhibits the reaction [Cyclophosphamide results in increased expression of P2RX3 protein] |
CTD |
PMID:23666265 |
|
NCBI chr 3:70,080,850...70,124,664
Ensembl chr 3:70,080,851...70,125,178
|
|
G |
P2rx5 |
purinergic receptor P2X 5 |
affects transport |
EXP |
Suramin affects transport ion flux of P2rx5 receptor |
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:57,777,737...57,789,426
Ensembl chr10:57,777,819...57,789,423
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
multiple interactions |
ISO |
Suramin inhibits the reaction [Poly I-C results in decreased expression of P2RX7 protein] |
CTD |
PMID:23516405 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
P2ry2 |
purinergic receptor P2Y2 |
decreases activity multiple interactions |
EXP ISO |
Suramin results in decreased activity of P2RY2 protein Suramin inhibits the reaction [Poly I-C results in decreased expression of P2RY2 protein] |
CTD |
PMID:15654852 PMID:23516405 |
|
NCBI chr 1:155,352,050...155,367,423
Ensembl chr 1:155,351,165...155,367,632
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
JTE 013 promotes the reaction [Suramin inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Suramin inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Suramin inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]; Suramin promotes the reaction [JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]] |
CTD |
PMID:18612546 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Shc1 |
SHC adaptor protein 1 |
multiple interactions increases expression |
EXP ISO |
Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of SHC1 protein] Suramin results in increased expression of SHC1 mRNA; Suramin results in increased expression of SHC1 protein |
CTD |
PMID:9710602 PMID:21778425 |
|
NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
Suramin inhibits the reaction [LMNA protein binds to and results in increased activity of SIRT1 protein]; Suramin results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein] [Suramin results in decreased activity of SIRT1 protein] which results in decreased susceptibility to resveratrol |
CTD |
PMID:18482975 PMID:23217256 PMID:24252177 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Tacr1 |
tachykinin receptor 1 |
multiple interactions |
EXP |
Suramin inhibits the reaction [Cyclophosphamide results in increased expression of TACR1 protein] |
CTD |
PMID:23666265 |
|
NCBI chr 4:114,920,844...115,089,733
Ensembl chr 4:114,920,844...115,089,733
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO |
Suramin results in increased expression of TNF protein |
CTD |
PMID:15914193 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
Suramin results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein] |
CTD |
PMID:18482975 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions |
ISO |
Suramin inhibits the reaction [Estradiol results in increased expression of VDR protein] |
CTD |
PMID:15930183 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
|
G |
P2ry12 |
purinergic receptor P2Y12 |
multiple interactions |
ISO |
Ticagrelor binds to and results in decreased activity of P2RY12 protein |
CTD |
PMID:19637098 |
|
NCBI chr 2:143,481,468...143,523,340
Ensembl chr 2:143,481,430...143,523,361
|
|
G |
Slc29a1 |
solute carrier family 29 member 1 |
multiple interactions |
ISO |
Ticagrelor inhibits the reaction [4-nitrobenzylthioinosine binds to SLC29A1 protein]; Ticagrelor inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine] |
CTD |
PMID:28041785 |
|
NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity decreases expression |
ISO EXP |
Ticlopidine results in decreased activity of ABCB11 protein Ticlopidine results in decreased expression of ABCB11 mRNA |
CTD |
PMID:22646477 PMID:27765674 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases activity increases expression |
ISO EXP |
Ticlopidine results in decreased activity of ABCC2 protein Ticlopidine results in increased expression of ABCC2 mRNA |
CTD |
PMID:22646477 PMID:27765674 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
EXP |
Ticlopidine results in increased expression of ABCC3 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases expression |
EXP |
Ticlopidine results in increased expression of ABCC4 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
Ticlopidine results in increased activity of CASP3 protein Palmitic Acid promotes the reaction [Ticlopidine results in increased activity of CASP3 protein] |
CTD |
PMID:22700542 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity multiple interactions |
ISO |
Ticlopidine results in increased activity of CASP7 protein Palmitic Acid promotes the reaction [Ticlopidine results in increased activity of CASP7 protein] |
CTD |
PMID:22700542 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
increases expression |
EXP |
Ticlopidine results in increased expression of COL18A1 protein |
CTD |
PMID:11353854 |
|
NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases activity |
ISO |
CYP1A2 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite; Ticlopidine inhibits the reaction [CYP1A2 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide] Ticlopidine results in decreased activity of CYP1A2 protein |
CTD |
PMID:10759690 PMID:19053182 PMID:19170597 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Ticlopidine results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions decreases activity |
ISO |
Ticlopidine binds to and results in decreased activity of CYP2B6 protein; Ticlopidine inhibits the reaction [CYP2B6 protein affects the metabolism of Endosulfan]; Ticlopidine inhibits the reaction [CYP2B6 protein results in increased metabolism of Bupropion] Ticlopidine results in decreased activity of CYP2B6 protein |
CTD |
PMID:16855053 PMID:19328226 PMID:23850985 PMID:28887089 PMID:33253783 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
multiple interactions decreases activity |
ISO |
CYP2C19 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite; Ticlopidine inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Ticlopidine inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Ticlopidine inhibits the reaction [CYP2C19 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide] Ticlopidine results in decreased activity of CYP2C19 protein |
CTD |
PMID:10759690 PMID:15333513 PMID:15860655 PMID:16049126 PMID:19053182 PMID:19170597 PMID:22652334 PMID:23850985 More...
|
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
multiple interactions |
ISO |
CYP2C8 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite |
CTD |
PMID:19170597 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions decreases activity |
ISO |
CYP2D6 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite Ticlopidine results in decreased activity of CYP2D6 protein |
CTD |
PMID:10759690 PMID:19170597 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases degradation increases response to substance multiple interactions |
ISO |
CYP3A4 protein results in increased degradation of Ticlopidine CYP3A4 protein results in increased susceptibility to Ticlopidine CYP3A4 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased degradation of Ticlopidine]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Ticlopidine]; Ticlopidine promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] |
CTD |
PMID:19170597 PMID:19299527 PMID:22651985 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
CYP3A5 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite |
CTD |
PMID:19170597 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
1-aminobenzotriazole inhibits the reaction [[Ticlopidine co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Ticlopidine results in increased expression of HMOX1 mRNA] |
CTD |
PMID:18227147 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Ticlopidine binds to and results in decreased activity of PGR protein |
CTD |
PMID:25752796 |
|
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
EXP |
Ticlopidine results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
multiple interactions |
ISO |
Ticlopidine affects the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
Ticlopidine affects the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904
|
|
G |
Thbs1 |
thrombospondin 1 |
affects expression |
ISO |
Ticlopidine affects the expression of THBS1 mRNA |
CTD |
PMID:14687031 |
|
NCBI chr 3:105,056,286...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression |
ISO |
Ticlopidine results in increased expression of UGT1A1 mRNA |
CTD |
PMID:18227147 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases activity |
ISO |
Ticlopidine results in decreased activity of VEGFA protein |
CTD |
PMID:26327247 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|